NO331103B1 - Polypeptid for induksjon av immunrespons mot Streptococcus Pneumoniae, polynukleotid og ekspresjonsvektor inneholdende dette samt vertscelle og fremgangsmate for produksjon av polypeptidet og vaksinesammensetning omfattende dette - Google Patents
Polypeptid for induksjon av immunrespons mot Streptococcus Pneumoniae, polynukleotid og ekspresjonsvektor inneholdende dette samt vertscelle og fremgangsmate for produksjon av polypeptidet og vaksinesammensetning omfattende detteInfo
- Publication number
- NO331103B1 NO331103B1 NO20026121A NO20026121A NO331103B1 NO 331103 B1 NO331103 B1 NO 331103B1 NO 20026121 A NO20026121 A NO 20026121A NO 20026121 A NO20026121 A NO 20026121A NO 331103 B1 NO331103 B1 NO 331103B1
- Authority
- NO
- Norway
- Prior art keywords
- polypeptide
- polynucleotide
- induction
- production
- host cell
- Prior art date
Links
- 229920001184 polypeptide Polymers 0.000 title abstract 4
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 4
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 4
- 239000000203 mixture Substances 0.000 title abstract 2
- 102000040430 polynucleotide Human genes 0.000 title abstract 2
- 108091033319 polynucleotide Proteins 0.000 title abstract 2
- 239000002157 polynucleotide Substances 0.000 title abstract 2
- 229960005486 vaccine Drugs 0.000 title abstract 2
- 241000193998 Streptococcus pneumoniae Species 0.000 title 1
- 239000013604 expression vector Substances 0.000 title 1
- 230000028993 immune response Effects 0.000 title 1
- 230000006698 induction Effects 0.000 title 1
- 238000004519 manufacturing process Methods 0.000 title 1
- 229940031000 streptococcus pneumoniae Drugs 0.000 title 1
- 208000035143 Bacterial infection Diseases 0.000 abstract 1
- 241001465754 Metazoa Species 0.000 abstract 1
- 206010061372 Streptococcal infection Diseases 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 208000022362 bacterial infectious disease Diseases 0.000 abstract 1
- 238000002405 diagnostic procedure Methods 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 238000010188 recombinant method Methods 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Communicable Diseases (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Pulmonology (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Plant Pathology (AREA)
- Gastroenterology & Hepatology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US21268300P | 2000-06-20 | 2000-06-20 | |
| PCT/CA2001/000908 WO2001098334A2 (en) | 2000-06-20 | 2001-06-19 | Streptococcus antigens |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO20026121D0 NO20026121D0 (no) | 2002-12-19 |
| NO20026121L NO20026121L (no) | 2003-02-13 |
| NO331103B1 true NO331103B1 (no) | 2011-10-10 |
Family
ID=22792041
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20026121A NO331103B1 (no) | 2000-06-20 | 2002-12-19 | Polypeptid for induksjon av immunrespons mot Streptococcus Pneumoniae, polynukleotid og ekspresjonsvektor inneholdende dette samt vertscelle og fremgangsmate for produksjon av polypeptidet og vaksinesammensetning omfattende dette |
Country Status (18)
| Country | Link |
|---|---|
| EP (2) | EP2281891A3 (enExample) |
| JP (2) | JP5051959B2 (enExample) |
| KR (1) | KR100927767B1 (enExample) |
| CN (2) | CN101260149B (enExample) |
| AR (1) | AR033980A1 (enExample) |
| AU (2) | AU2001270381B2 (enExample) |
| CA (1) | CA2413450C (enExample) |
| CZ (1) | CZ2003154A3 (enExample) |
| EA (1) | EA006232B1 (enExample) |
| HU (1) | HU228706B1 (enExample) |
| IL (2) | IL153558A0 (enExample) |
| MX (1) | MXPA03000103A (enExample) |
| NO (1) | NO331103B1 (enExample) |
| NZ (1) | NZ553554A (enExample) |
| PL (1) | PL214229B1 (enExample) |
| TR (1) | TR200704553T2 (enExample) |
| UY (1) | UY26783A1 (enExample) |
| WO (1) | WO2001098334A2 (enExample) |
Families Citing this family (77)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7128918B1 (en) | 1998-12-23 | 2006-10-31 | Id Biomedical Corporation | Streptococcus antigens |
| US7074415B2 (en) | 2000-06-20 | 2006-07-11 | Id Biomedical Corporation | Streptococcus antigens |
| US7262024B2 (en) | 2001-12-20 | 2007-08-28 | Id Biomedical Corporation | Streptococcus antigens |
| TWI457133B (zh) | 2005-12-13 | 2014-10-21 | Glaxosmithkline Biolog Sa | 新穎組合物 |
| JP5792920B2 (ja) | 2005-12-22 | 2015-10-14 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | ワクチン |
| GB0607088D0 (en) | 2006-04-07 | 2006-05-17 | Glaxosmithkline Biolog Sa | Vaccine |
| SI2097102T1 (sl) | 2006-09-07 | 2012-09-28 | Glaxosmithkline Biolog Sa | Kombinirano cepivo, ki ima zmanjšane količine antigena za poliovirus |
| JP2010525035A (ja) | 2007-05-02 | 2010-07-22 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | ワクチン |
| EA200901578A1 (ru) | 2007-06-26 | 2010-08-30 | Глаксосмитклайн Байолоджикалс С.А. | Вакцина, содержащая конъюгаты капсульных полисахаридов streptococcus pneumoniae |
| CA2694466A1 (en) * | 2007-07-23 | 2009-01-29 | Sanofi Pasteur Limited | Immunogenic polypeptides and monoclonal antibodies |
| KR20110009157A (ko) | 2008-04-16 | 2011-01-27 | 글락소스미스클라인 바이오로지칼즈 에스.에이. | 백신 |
| WO2010036945A2 (en) | 2008-09-26 | 2010-04-01 | The Regents Of The University Of Michigan | Nanoemulsion therapeutic compositions and methods of using the same |
| DK2424562T3 (en) | 2009-04-30 | 2015-12-07 | Coley Pharm Group Inc | Pneumococcal vaccine and uses thereof |
| WO2010132833A1 (en) | 2009-05-14 | 2010-11-18 | The Regents Of The University Of Michigan | Streptococcus vaccine compositions and methods of using the same |
| US20120135037A1 (en) | 2009-06-01 | 2012-05-31 | Mizel Steven B | Flagellin fusion proteins and conjugates comprising pneumococcus antigens and methods of using the same |
| KR101660578B1 (ko) | 2009-09-03 | 2016-09-27 | 화이자 백신스 엘엘씨 | Ｐｃｓｋ９ 백신 |
| GB201003920D0 (en) | 2010-03-09 | 2010-04-21 | Glaxosmithkline Biolog Sa | Method of treatment |
| GB201003924D0 (en) | 2010-03-09 | 2010-04-21 | Glaxosmithkline Biolog Sa | Immunogenic composition |
| KR101272351B1 (ko) | 2010-04-23 | 2013-06-07 | 이화여자대학교 산학협력단 | 새로운 카나마이신 화합물, 카나마이신 생산 스트렙토마이세스 속 미생물 및 카나마이신의 생산 방법 |
| WO2012131504A1 (en) | 2011-03-02 | 2012-10-04 | Pfizer Inc. | Pcsk9 vaccine |
| KR20140033127A (ko) | 2011-05-17 | 2014-03-17 | 글락소스미스클라인 바이오로지칼즈 에스.에이. | 스트렙토코쿠스 뉴모니애에 대한 백신 |
| WO2015095868A1 (en) | 2013-12-20 | 2015-06-25 | Wake Forest University Health Sciences | Methods and compositions for increasing protective antibody levels induced by pneumococcal polysaccharide vaccines |
| US11160855B2 (en) | 2014-01-21 | 2021-11-02 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
| FI3583947T3 (fi) | 2014-01-21 | 2023-10-12 | Pfizer | Streptococcus pneumoniaen kapselipolysakkaridit ja niiden konjugaatit |
| BR112016015835B1 (pt) | 2014-01-21 | 2023-12-26 | Pfizer Inc | Processo de preparação de conjugados compreendendo polissacarídeos capsulares de streptococcus pneumoniae |
| IL312327B2 (en) | 2014-01-21 | 2026-02-01 | Pfizer | Immunogenic preparations comprising conjugated capsular saccharide antigens and their uses |
| ES2930318T3 (es) | 2014-02-14 | 2022-12-09 | Pfizer | Conjugados glucoproteicos inmunogénicos |
| PL3244917T3 (pl) | 2015-01-15 | 2023-07-17 | Pfizer Inc. | Kompozycje immunogenne do zastosowania w szczepionkach przeciwko pneumokokom |
| KR20250058066A (ko) | 2015-07-21 | 2025-04-29 | 화이자 인코포레이티드 | 접합된 캡슐형 사카라이드 항원을 포함하는 면역원성 조성물, 그를 포함하는 키트 및 그의 용도 |
| GB201518684D0 (en) | 2015-10-21 | 2015-12-02 | Glaxosmithkline Biolog Sa | Vaccine |
| US10786561B2 (en) | 2015-11-20 | 2020-09-29 | Pfizer Inc. | Immunogenic compositions for use in pneumococcal vaccines |
| BR112019014833A2 (pt) | 2017-01-20 | 2020-04-14 | Pfizer | composições imunogênicas para uso em vacinas pneumococais |
| CN110225757A (zh) | 2017-01-31 | 2019-09-10 | 默沙东公司 | 由肺炎链球菌血清型19f生产荚膜多糖蛋白缀合物的方法 |
| WO2018144439A1 (en) | 2017-01-31 | 2018-08-09 | Merck Sharp & Dohme Corp. | Methods for making polysaccharide-protein conjugates |
| CN110392690B (zh) | 2017-02-24 | 2024-01-30 | 默沙东有限责任公司 | 肺炎球菌缀合物疫苗制剂 |
| GB201711635D0 (en) | 2017-07-19 | 2017-08-30 | Glaxosmithkline Biologicals Sa | Immunogenic composition |
| HUE068482T2 (hu) | 2017-09-07 | 2025-01-28 | Merck Sharp & Dohme Llc | Pneumococcus-poliszacharidok és azok felhasználása immunogén poliszacharid-hordozóprotein konjugátumokban |
| EP3720483B1 (en) | 2017-12-06 | 2025-11-19 | Merck Sharp & Dohme LLC | Compositions comprising streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof |
| US11260119B2 (en) | 2018-08-24 | 2022-03-01 | Pfizer Inc. | Escherichia coli compositions and methods thereof |
| US20220016229A1 (en) | 2018-12-12 | 2022-01-20 | Pfizer Inc. | Immunogenic Multiple Hetero-Antigen Polysaccharide-Protein Conjugates and uses thereof |
| EP3897705A2 (en) | 2018-12-19 | 2021-10-27 | Merck Sharp & Dohme Corp. | Compositions comprising streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof |
| JP7239509B6 (ja) | 2019-02-22 | 2023-03-28 | ファイザー・インク | 細菌多糖類を精製するための方法 |
| US20220184199A1 (en) | 2019-04-10 | 2022-06-16 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof |
| JP2022542316A (ja) | 2019-07-31 | 2022-09-30 | サノフィ パスツール インコーポレイテッド | 多価肺炎球菌多糖体－タンパク質コンジュゲート組成物およびその使用方法 |
| AU2020375214B2 (en) | 2019-11-01 | 2024-02-08 | Pfizer Inc. | Escherichia coli compositions and methods thereof |
| CN115362177A (zh) | 2020-02-21 | 2022-11-18 | 辉瑞公司 | 糖类的纯化 |
| KR20220143910A (ko) | 2020-02-23 | 2022-10-25 | 화이자 인코포레이티드 | 에스케리키아 콜라이 조성물 및 그의 방법 |
| US20230383324A1 (en) | 2020-10-22 | 2023-11-30 | Pfizer Inc. | Methods for purifying bacterial polysaccharides |
| MX2023004912A (es) | 2020-10-27 | 2023-05-16 | Pfizer | Composiciones de escherichia coli y metodos de las mismas. |
| US12138302B2 (en) | 2020-10-27 | 2024-11-12 | Pfizer Inc. | Escherichia coli compositions and methods thereof |
| CA3200602A1 (en) | 2020-11-04 | 2022-05-12 | Pfizer Inc. | Immunogenic compositions for use in pneumococcal vaccines |
| US12357681B2 (en) | 2020-12-23 | 2025-07-15 | Pfizer Inc. | E. coli FimH mutants and uses thereof |
| TW202245835A (zh) | 2021-02-04 | 2022-12-01 | 美商默沙東有限責任公司 | 用於肺炎球菌結合物疫苗之奈米乳化液佐劑組合物 |
| WO2022234416A1 (en) | 2021-05-03 | 2022-11-10 | Pfizer Inc. | Vaccination against pneumoccocal and covid-19 infections |
| CA3218544A1 (en) | 2021-05-03 | 2022-11-10 | Pfizer Inc. | Vaccination against bacterial and betacoronavirus infections |
| CA3221075A1 (en) | 2021-05-28 | 2022-12-01 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
| JP7714690B2 (ja) | 2021-05-28 | 2025-07-29 | ファイザー・インク | コンジュゲートさせた莢膜糖抗原を含む免疫原性組成物およびその使用 |
| JP2025508749A (ja) | 2022-01-13 | 2025-04-10 | ファイザー・インク | コンジュゲートさせた莢膜糖抗原を含む免疫原性組成物およびその使用 |
| WO2023161817A1 (en) | 2022-02-25 | 2023-08-31 | Pfizer Inc. | Methods for incorporating azido groups in bacterial capsular polysaccharides |
| US20250312433A1 (en) | 2022-05-11 | 2025-10-09 | Pfizer Inc. | Process for Producing of Vaccine Formulations With Preservatives |
| US20260130987A1 (en) | 2022-10-19 | 2026-05-14 | Pfizer Inc. | Vaccination against pneumoccocal and covid-19 infections |
| WO2024110827A1 (en) | 2022-11-21 | 2024-05-30 | Pfizer Inc. | Methods for preparing conjugated capsular saccharide antigens and uses thereof |
| EP4622665A2 (en) | 2022-11-22 | 2025-10-01 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
| CN120513083A (zh) | 2022-12-01 | 2025-08-19 | 辉瑞大药厂 | 肺炎链球菌缀合物疫苗制剂 |
| WO2024166008A1 (en) | 2023-02-10 | 2024-08-15 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
| AU2024246082A1 (en) | 2023-03-30 | 2025-10-16 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
| PE20252779A1 (es) | 2023-04-14 | 2025-12-22 | Pfizer | Composiciones inmunogenas que comprenden antigenos de sacarido capsular conjugados y usos de estos |
| WO2024224266A1 (en) | 2023-04-24 | 2024-10-31 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
| PE20260294A1 (es) | 2023-05-18 | 2026-02-10 | Merck Sharp And Dohme Llc | Compuestos y formulaciones adyuvantes utiles en vacunas neumococicas |
| CN121263203A (zh) | 2023-05-19 | 2026-01-02 | 葛兰素史克生物有限公司 | 诱导对呼吸道合胞病毒和肺炎链球菌感染的免疫反应的方法 |
| TW202527906A (zh) | 2023-09-14 | 2025-07-16 | 美商輝瑞股份有限公司 | 包含經結合之肺炎鏈球菌莢膜醣抗原之佐劑化致免疫性組成物及其用途 |
| TW202539728A (zh) | 2023-11-16 | 2025-10-16 | 美商默沙東有限責任公司 | 肽共軛物疫苗組合物及治療阿茲海默氏症之方法 |
| WO2025133971A1 (en) | 2023-12-23 | 2025-06-26 | Pfizer Inc. | Improved methods for producing bacterial capsular saccharide glycoconjugates |
| WO2025186705A2 (en) | 2024-03-06 | 2025-09-12 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
| TW202602467A (zh) | 2024-03-11 | 2026-01-16 | 美商輝瑞股份有限公司 | 包含經共軛之大腸桿菌糖的免疫原性組成物及其用途 |
| WO2025219904A1 (en) | 2024-04-19 | 2025-10-23 | Pfizer Inc. | Improved methods for producing glycoconjugates by reductive amination in aprotic solvent |
| WO2025219908A2 (en) | 2024-04-19 | 2025-10-23 | Pfizer Inc. | Media and fermentation methods for polysaccharide production in bacterial cell culture |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4431739A (en) | 1979-11-05 | 1984-02-14 | Genentech, Inc. | Transformant bacterial culture capable of expressing heterologous protein |
| US4425437A (en) | 1979-11-05 | 1984-01-10 | Genentech, Inc. | Microbial polypeptide expression vehicle |
| US4338397A (en) | 1980-04-11 | 1982-07-06 | President And Fellows Of Harvard College | Mature protein synthesis |
| US5866135A (en) * | 1994-04-21 | 1999-02-02 | North American Vaccine, Inc. | Group A streptococcal polysaccharide immunogenic compositions and methods |
| EP0831894A1 (en) * | 1995-06-07 | 1998-04-01 | Alberta Research Council | Immunogenic and immunostimulatory oligosaccharide compositions and methods of making and using them |
| ATE348887T1 (de) | 1996-10-31 | 2007-01-15 | Human Genome Sciences Inc | Streptococcus pneumoniae antigene und impfstoffe |
| EP1017828A1 (en) * | 1997-09-24 | 2000-07-12 | Regents Of The University Of Minnesota | HUMAN COMPLEMENT C3-DEGRADING PROTEINASE FROM $i(STREPTOCOCCUS PNEUMONIAE) |
| WO2000006737A2 (en) * | 1998-07-27 | 2000-02-10 | Microbial Technics Limited | Streptococcus pneumoniae proteins and nucleic acid molecules |
| CN1263510C (zh) * | 1998-08-19 | 2006-07-12 | 巴克斯特健康护理股份有限公司 | 多糖－蛋白质缀合物或寡糖－蛋白质缀合物、其制备方法及其应用 |
| EP1115875A1 (en) * | 1998-09-24 | 2001-07-18 | Regents Of The University Of Minnesota | Human complement c3-degrading polypeptide from streptococcus pneumoniae |
| CA2355364C (en) | 1998-12-21 | 2014-03-18 | Medimmune, Inc. | Streptococcus pneumoniae proteins and immunogenic fragments for vaccines |
| PL205041B1 (pl) * | 1998-12-23 | 2010-03-31 | Id Biomedical Corp | Izolowany polinukleotyd, wektor zawierający izolowany polinukleotyd, komórka gospodarza transfekowana lub transformowana za pomocą tego wektora, sposób wytwarzania polipeptydu kodowanego przez izolowany polinukleotyd, izolowany polipeptyd, chimeryczny polipeptyd, kompozycja do szczepionek zawierająca polipeptyd oraz jej zastosowanie w leczeniu lub zapobieganiu zakażeniu osobnika paciorkowcem |
-
2001
- 2001-06-19 WO PCT/CA2001/000908 patent/WO2001098334A2/en not_active Ceased
- 2001-06-19 MX MXPA03000103A patent/MXPA03000103A/es active IP Right Grant
- 2001-06-19 CN CN200710181645.XA patent/CN101260149B/zh not_active Expired - Fee Related
- 2001-06-19 KR KR1020027017453A patent/KR100927767B1/ko not_active Expired - Fee Related
- 2001-06-19 CZ CZ2003154A patent/CZ2003154A3/cs unknown
- 2001-06-19 NZ NZ553554A patent/NZ553554A/en not_active IP Right Cessation
- 2001-06-19 AU AU2001270381A patent/AU2001270381B2/en not_active Ceased
- 2001-06-19 EP EP10179497A patent/EP2281891A3/en not_active Withdrawn
- 2001-06-19 CN CN01814388A patent/CN1449446A/zh active Pending
- 2001-06-19 PL PL360413A patent/PL214229B1/pl unknown
- 2001-06-19 EA EA200201280A patent/EA006232B1/ru not_active IP Right Cessation
- 2001-06-19 AU AU7038101A patent/AU7038101A/xx not_active Withdrawn
- 2001-06-19 CA CA2413450A patent/CA2413450C/en not_active Expired - Fee Related
- 2001-06-19 IL IL15355801A patent/IL153558A0/xx unknown
- 2001-06-19 EP EP01949136A patent/EP1303612A2/en not_active Withdrawn
- 2001-06-19 TR TR2007/04553T patent/TR200704553T2/xx unknown
- 2001-06-19 HU HU0301656A patent/HU228706B1/hu not_active IP Right Cessation
- 2001-06-19 JP JP2002504289A patent/JP5051959B2/ja not_active Expired - Fee Related
- 2001-06-20 AR ARP010102945A patent/AR033980A1/es not_active Application Discontinuation
- 2001-06-20 UY UY26783A patent/UY26783A1/es not_active Application Discontinuation
-
2002
- 2002-12-19 IL IL153558A patent/IL153558A/en not_active IP Right Cessation
- 2002-12-19 NO NO20026121A patent/NO331103B1/no not_active IP Right Cessation
-
2012
- 2012-05-23 JP JP2012117846A patent/JP5889103B2/ja not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20026121L (no) | Streptokokkantigener | |
| AR029322A1 (es) | Un polinucleotido de estreptococo aislado que codifica un polipeptido capaz de generar anticuerpos que tienen especificidad de union para un segundo polipeptido de secuencias reveladas, los polipeptidos mencionados y un proceso para su fabricacion, un polipeptido quimerico, compuesto por dichos segu | |
| NO20004161L (no) | Gruppe B streptokoccus antigener | |
| BR0208944A (pt) | quadros de leitura aberta de streptococus pneumoniae codificando os antìgenos de polipeptìdeos e seus usos | |
| DE69739981D1 (de) | Streptococcus pneumoniae-Antigene und Impfstoffe | |
| ATE522541T1 (de) | Bakterielle adhäsine konformere | |
| MXPA03009294A (es) | Proteinas de superficie de streptococcus pyogenes. | |
| ATE323721T1 (de) | Cholin-bindendes protein, welches als gegen pneumokokken gerichtetes vakzin verwendet wird | |
| BR0015137A (pt) | Peptìdeos antigênicos de neisseria | |
| ATE198051T1 (de) | Pneumokokken-polysaccharid-rekombinante- pneumolysin-konjugate als impfstoffe für die immunisierung gegen pneumokokken-infektionen | |
| NO975752L (no) | Varmesjokkproteiner fra streptokokker i HSP70 familien | |
| Choi et al. | Analysis of Streptococcus pneumoniae secreted antigens by immuno-proteomic approach | |
| BR0108654A (pt) | Composição imunogênica, polipeptìdeo isolado, vetor de expressão ou um microorganismo vivo recombinante, célula hospedeira, processos para produzir uma composição imunogênica e um polipeptìdeo ou um fragmento imunogênico do mesmo, uso de um polipeptìdeo ou de um polinucleotìdeo que codifica um polipeptìdeo, método para o tratamento de um indivìduo pela imunoprofilaxia ou terapia, anticorpo, agonista ou antagonista ao polipeptìdeo, composto, e, processos para diagnosticar, uma doença ou uma suscetibilidade a uma doença e a presença de câncer colorretal ou uma suscetibilidade ao câncer colorretal, em um indivìduo | |
| WO2003065973A8 (en) | Multivalent streptococcal vaccine compositions and methods for use | |
| De et al. | Purification and characterization of Streptococcus pneumoniae palmitoylated pneumococcal surface adhesin A expressed in Escherichia coli | |
| DE60118359D1 (de) | Humanische pellino-polypeptide | |
| NO20025146L (no) | Isolering og karakterisering av csa-operonet (ETEC-CS4 pili) og fremgangsmåter for anvendelse derav | |
| WO2004020609A3 (en) | Streptococcus pneumoniae antigens for diagnosis, treatment and prevention of active infection | |
| BR9908476A (pt) | Peptìdeo, composição terapêutica, e, processo para conferir imunidade protetora a um paciente, contra a infecção de s. pneumoniae | |
| EP1219635A3 (en) | Chlamydia pneumoniae antigenes | |
| Wästfelt et al. | The Rib and α Proteins Define a Family of Group B Streptococcal Surface Proteins that Confer Protective Immunity | |
| DE60031106D1 (de) | Fluordesoxyuridin-resistente streptococcus gordonii stämme | |
| Ge | Identification of the surface-associated proteins and functions of enolase of Streptococcus mutans | |
| BR0111886A (pt) | Antìgeno para estreptococos | |
| EP1950302A3 (en) | Streptococcus antigens |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM1K | Lapsed by not paying the annual fees |